Not Signed In - Cytokinetics Announces Initiation Of Phase I Clinical Trial For Oral Administration Of CK-1827452
Thu, 24 Aug 2006 07:00 AM EST
... Cytokinetics, Incorporated (Nasdaq: CYTK) announced the initiation of aPhase I clinical trial evaluating the pharmacokinetic profile of CK-1827452when administered orally to healthy volunteers. CK-1827452 is a directcardiac myosin activator under evaluation as a potential treatment forpatients with acute and chronic heart failure. [click link for full article] ...
Related Topics
- Clinical Trials
- CK
- Iohexol (oral/rectal administration)
- CK-MB
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Tarceva
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Oral Cancer
- Bevacizumab Injection
- Clinical Growth Charts
- Oral Health
- Crohn's Disease
- Pancreatic Cancer
- Patient Issues
- Amoxicillin Oral Suspension
- Zidovudine Oral Syrup
- Hypnotherapy
email this page
print this page
bookmark this page
feedback on this page
